Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.

@article{Schlag1992ActiveSI,
  title={Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial.},
  author={Peter M. Schlag and M. Manasterski and T Gerneth and Peter Hohenberger and Margret Dueck and Christian Herfarth and Winfrid Liebrich and Volker Schirrmacher},
  journal={Cancer immunology, immunotherapy : CII},
  year={1992},
  volume={35 5},
  pages={325-30}
}
A group of 23 colorectal cancer patients were treated by a new type of active specific immunotherapy (ASI) following complete surgical resection of liver metastases (RO resection). For ASI treatment we used a vaccine consisting of 1 x 10(7) autologous, irradiated (200 Gy) metastases-derived tumor cells incubated with 32 hemagglutination units (HU) of Newcastle disease virus (NDV). The adjuvant vaccine therapy was started 2 weeks after surgery and was repeated five times at 14-days intervals… CONTINUE READING